COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) major shareholder George Jay Goldsmith sold 23,881 shares of the stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $8.53, for a total value of $203,704.93. Following the completion of the sale, the insider now directly owns 3,986,523 shares of the company’s stock, valued at $34,005,041.19. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
George Jay Goldsmith also recently made the following trade(s):
- On Monday, April 1st, George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock. The stock was sold at an average price of $8.96, for a total value of $230,720.00.
- On Tuesday, March 12th, George Jay Goldsmith sold 15,740 shares of COMPASS Pathways stock. The stock was sold at an average price of $10.58, for a total value of $166,529.20.
- On Monday, January 22nd, George Jay Goldsmith sold 25,750 shares of COMPASS Pathways stock. The stock was sold at an average price of $8.35, for a total value of $215,012.50.
- On Friday, January 19th, George Jay Goldsmith sold 20,205 shares of COMPASS Pathways stock. The stock was sold at an average price of $7.99, for a total value of $161,437.95.
COMPASS Pathways Stock Performance
NASDAQ:CMPS opened at $8.38 on Friday. The stock has a market cap of $519.06 million, a P/E ratio of -3.51 and a beta of 2.48. The company has a quick ratio of 13.33, a current ratio of 13.33 and a debt-to-equity ratio of 0.14. COMPASS Pathways plc has a twelve month low of $5.01 and a twelve month high of $12.75. The business’s 50-day moving average price is $9.94 and its two-hundred day moving average price is $8.35.
Hedge Funds Weigh In On COMPASS Pathways
A number of large investors have recently modified their holdings of CMPS. Raymond James & Associates raised its holdings in shares of COMPASS Pathways by 4.1% during the 1st quarter. Raymond James & Associates now owns 34,435 shares of the company’s stock valued at $444,000 after buying an additional 1,341 shares in the last quarter. BlackRock Inc. lifted its position in COMPASS Pathways by 27.3% in the first quarter. BlackRock Inc. now owns 275,338 shares of the company’s stock valued at $3,549,000 after purchasing an additional 59,018 shares during the last quarter. Penserra Capital Management LLC lifted its position in COMPASS Pathways by 39.8% in the first quarter. Penserra Capital Management LLC now owns 29,000 shares of the company’s stock valued at $277,000 after purchasing an additional 8,252 shares during the last quarter. Renaissance Technologies LLC lifted its position in COMPASS Pathways by 110.3% in the first quarter. Renaissance Technologies LLC now owns 129,200 shares of the company’s stock valued at $1,665,000 after purchasing an additional 67,770 shares during the last quarter. Finally, PFS Investments Inc. lifted its position in COMPASS Pathways by 23.9% in the first quarter. PFS Investments Inc. now owns 38,171 shares of the company’s stock valued at $492,000 after purchasing an additional 7,359 shares during the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several research analysts have commented on CMPS shares. HC Wainwright restated a “buy” rating and issued a $120.00 target price on shares of COMPASS Pathways in a research note on Friday, March 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of COMPASS Pathways in a report on Thursday. Finally, Morgan Stanley assumed coverage on COMPASS Pathways in a report on Monday, April 1st. They issued an “overweight” rating and a $30.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $47.40.
Read Our Latest Report on CMPS
About COMPASS Pathways
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.
Read More
- Five stocks we like better than COMPASS Pathways
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Comprehensive Analysis of PayPal Stock
- Why Invest in 5G? How to Invest in 5G Stocks
- Intuitive Surgical Stock Can Trend Much Higher This Year
- How to Use Stock Screeners to Find Stocks
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for COMPASS Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COMPASS Pathways and related companies with MarketBeat.com's FREE daily email newsletter.